Tempus AI IPO
Tempus AI is a precision medicine company that uses artificial intelligence and data analytics to help physicians make more informed treatment decisions, particularly in oncology. The company builds and operates a platform that analyzes clinical and molecular data to provide personalized therapy recommendations. Investors are interested in its potential to transform cancer care through AI-driven insights and its growing database of genomic and clinical information.
Key Facts
| Industry | Healthcare AI |
| Founded | 2015 |
| Headquarters | Chicago, IL |
| Employees | ~2,600 |
| Website | tempus.com |
| Funding | Public company (IPO June 2024) |
About Tempus AI
Tempus AI represents the artificial intelligence and machine learning capabilities of Tempus, focusing specifically on developing AI-powered solutions for precision medicine. The company leverages its massive dataset of clinical and molecular information to train algorithms that can identify patterns in cancer treatment responses, predict patient outcomes, and recommend personalized therapies.
The AI platform analyzes multimodal data including genomic sequencing results, medical imaging, clinical notes, and treatment histories to generate insights that help oncologists make more informed decisions. Tempus AI's algorithms are integrated into clinical workflows at major cancer centers and have been validated in numerous peer-reviewed studies, demonstrating the potential to improve both patient outcomes and operational efficiency in cancer care.
IPO Status
Tempus AI completed its initial public offering in June 2024, trading on NASDAQ under the ticker symbol "TEM." The company raised approximately $411 million in its IPO, pricing shares at $37 each. The offering was notable as one of the significant healthcare AI IPOs of 2024, reflecting continued investor interest in AI-powered healthcare solutions. As a newly public company, Tempus is focused on scaling its precision medicine platform and expanding its partnerships with healthcare providers and pharmaceutical companies. The company continues to build its proprietary dataset while working to demonstrate the clinical and economic value of its AI-driven approach to personalized medicine.
Competitors
Frequently Asked Questions
Does Tempus AI have a stock?
Yes, Tempus AI completed its IPO in June 2024 and is now publicly traded. The company trades on NASDAQ under the ticker symbol "TEM."
When is the Tempus AI IPO date?
Tempus AI already completed its IPO in June 2024, so there is no upcoming public offering. The company recently became publicly traded.
How can I buy Tempus AI stock?
You can buy Tempus AI stock through any brokerage account as it trades on NASDAQ under ticker "TEM." The stock has been available for public trading since June 2024.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts